Basic Information
| LncRNA/CircRNA Name | NNT-AS1 |
| Synonyms | NA |
| Region | GRCh38_5:43571594-43603230 |
| Ensemble | ENSG00000248092 |
| Refseq | NR_073113 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot |
| Sample | non small cell lung cancer tissues, cell lines( A549, SPCA1) |
| Expression Pattern | up-regulated |
| Function Description | expression of lncRNA NNT-AS1 in drug-resistant cells was higher than that in parental cells. Clone formation assay and flow cytometry revealed that interfering in the expression of lncRNA NNT-AS1 could inhibit the proliferation, promote the apoptosis and cell cycle arrest of drug-resistant cells. |
| Pubmed ID | 30070323 |
| Year | 2018 |
| Title | LncRNA NNT-AS1 Is a Major Mediator of Cisplatin Chemoresistance in Non-Small Cell Lung Cancer Through MAPK/Slug Pathway. |
External Links
| Links for NNT-AS1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |